The largest subunit of the RNA polymerase II (pol II) contains at the carboxy-terminus a peculiar repetitive sequence that consists of 52 tandem repeats of the consensus motif Tyr-Ser-Pro-Thr-Ser-Pro-Ser, referred to as the C-terminal domain (CTD). Upon transcriptional initiation/promoter clearance, the CTD becomes extensively phosphorylated and apparently remains so during elongation. While the underphosphorylated CTD plays a role in transcriptional initiation, recent evidence couples the highly phosphorylated CTD to RNA processing, namely polyadenylation and splicing.
The largest subunit of RNA polymerase II (pol II), which is dedicated to the transcription of messenger RNA in eukaryotic cells, can be phosphorylated extensively on its carboxyterminal domain (CTD). The CTD consists of multiple tandem repeats with the consensus amino acid sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser (Corden ei a/., 1985; Dahmus, 1995) , which is conserved among different species. However, the number of repeats appears to correlate with the degree of complexity of the organism (Corden and Ingles, 1992) . In the mammalian enzyme, the distal repeats diverge from the heptapeptide consensus at many positions, which might mean that additional CTD functions have evolved in higher eukaryotes (Barron-Casella and Corden, 1992) . The CTD is essential for the survival of any cell, from yeast to mammals, and contributes to the regulation of transcription (Dahmus, 1995; Gerberei a/., 1995; Koleske and Young, 1995) .
The hypophosphorylated form of pol II is preferentially associated with the preinitiation complex. Consistent with this finding, the non-phosphorylated form of the CTD interacts directly with the basal transcription factors TBP and TRIE (Ushevaef a/., 1992; Maxon etal., 1994) . In addition, there is genetic and biochemical evidence that the CTD undergoes multiple interactions with the so-called mediator or SRB complex, a multiprotein complex containing more than 20 proteins implicated in assisting transcriptional activation. The mediator is part of a larger initiation competent pol II holoenzyme complex (Emili and Ingles, 1995; Wilson ef a/., 1996) . Accordingly, a holoenzyme complex isolated from mammalian nuclei contains the unphosphorylated form of pol II (Ossipowefa/., 1995) .
The strongly phosphorylated form of pol II, with an apparent molecular weight of 240 kDa, is typically found in transcriptional elongation complexes (Kang and Dahmus, 1993; O'Brien etal., 1994) . CTD phosphorylation correlates with promoter clearance and the stimulation of transcriptional elongation (reviewed in Dahmus, 1995) . The CTD can be phosphorylated by several serine/threonine and apparently also tyrosine kinases, suggesting that a diversity of phosphorylated CTD forms might exist (Dahmus, 1995) . Little was known about the possible interaction partners and functions of the phosphorylated CTD. Recently however, the phosphorylated pol II was detected in the nuclear 'speckles', which are interconnected domains containing most of the known splicing factors (Bregman ef a/., 1995; Mortillaro ef a/., 1996) . The nuclear speckles are thought to be sites of storage and/or assembly of splicing factors and are found in close spatial association with active sites of transcription (Spector, 1993; Xing et a/., 1995) . Consistent with this observation, the hyperphosphorylated form of pol II can be immunoprecipitated together with different splicing factors (Mortillaro ef a/., 1996; Vincent ef a/., 1996) . Earlier microscopic and biochemical studies indicated that splicing, at least in part, occurs concomitantly with transcription (Fakan, 1994; Mattaj, 1994) . Indeed, in situ immunofluorescent hybridisation studies have demonstrated that the sites of transcription and splicing of several cellular genes co-localise to small defined foci, often in the immediate vicinity of the nuclear speckles (Xingef a/., 1993; Zhang ef a/., 1994; Xing efa/.,1995).
The molecular mechanisms that couple RNA processing with transcription have not been characterised. Recent findings suggest a possible role for the CTD in linking these processes, as an interaction partner for proteins with possible roles in RNA processing. Also, it has become apparent that truncations of the CTD inhibit not only RNA splicing but also processing of the 3' end and termination of transcription downstream of the poly (A) site. Interestingly, cleavage-polyadenylation factors CPSF and CstF bind specifically to CTD affinity columns (McCrackenefa/., 1997) .
In a yeast two-hybrid screen, we have isolated a group of serine/arginine-rich proteins that interact with the CTD of murine RNA pol II. One of these proteins, a serine/arginine-rich cyclophilin termed SRcyp, is a component of the nuclear speckles and might mediate the assembly of a multiprotein complex linking RNA processing with transcription (Bourquin ef a/., 1997). The fusion chimera of the 52 mouse CTD repeats to the GAL4 DNA-binding domain is phosphorylated and recognised by monoclonal antibodies specific for the phosphorylated form of pol II. The same antibody recognises the phosphorylated form of pol II in larger protein complexes with splicing factors in mammalian cells (Mortillaro ef a/., 1996) . Thus the CTD fusion protein is probably phosphorylated in yeast on the sites that are also phosphorylated in vivo. We have confirmed the interaction of SRcyp with the phosphorylated form of the CTD in mammalian cells (Bourquin ef a/., 1997) . A set of large serine/arginine-rich proteins that interact with the CTD have been isolated in a similar yeast two-hybrid approach by J. Corden and his colleagues (Yuryev ef a/., 1996) . These authors have also reported the inhibition of cell-free splicing reactions upon incubation with either anti-CTD antibodies or synthetic CTD peptides, providing additional evidence for a possible role of the CTD in splicing. We report here on two CTD-binding proteins that are related but distinct from the two mammalian serine/arginine-rich proteins isolated by Yuryev ef a/. (1996) in yeast, further supporting the idea that transcription and RNA processing may be directly coupled in the mammalian cell.
In our two-hybrid assay we have screened a human lymphocyte cDNA library in the yeast strain Y153 expressing the CTD fused to the GAL4 DMA binding domain according to Durfee ef a/. (1993) . Two sets of overlapping cDNAs were isolated (the SRrp129 family: four independent clones, and the C10 family: three independent clones). According to the unifying nomenclature proposed by J. Corden (Johns Hopkins University, Baltimore) for published and unpublished CTD-associated SR-related proteins, our SRrp129 might also be renamed CASP11 for CTD associated SR protein 11; and C10, CASP12. The positive clones did not interact with highly negatively charged heterologous proteins fused to the GAL4 DMA binding domain, namely the Cbl-2 oncogene from amino acids residues 352-469 and the portion of nucleolin from amino acids 170-277 as described in Seipel ef a/. (1992) . Also, the activation of the selectable marker genes in yeast cells by the SRrp129 and C10 clones was strictly dependent on the presence of the CTD, underlying the notion that these interactions were specific (data not shown).
In the yeast two-hybrid assay, SRrpI 29 and C10 also interacted with eight tandem consensus CTD repeats fused to the GAL4 DMA binding domain constructed by Seipel ef a/. (1993) and with the CTD of the yeast Saccharomyces cerevisiae (a kind gift of R. Young, MIT), thus showing that this interaction can occur with a limited number of consensus heptapeptide repeats.
The sequence analysis of the SRrp129 and C10 family revealed a conserved domain of about one hundred amino acids in length that was present in all the clones at their C-termini (Figure 1 ). This prompted us to test whether this region was sufficient for the interaction with the CTD. In order to define the CTD interaction domain rapidly, we tested an improved version of the yeast interaction trap assay that we have described recently (Stagljar ef a/., 1996; Figure 2 ). To generate random cDNA fragments, we digested the SRrpI 29 cDNA insert (1436 bp) subcloned in pBluescript, with DNasel in the presence of manganese (II), thus replacing the previous method of sonication used in the fragmentation of DNA. We exploited the fact that the properties of DNase I are altered when manganese (II) replaces magnesium (II). In the presence of manganese (II), the enzyme generates double strand breaks, which may The CTD interaction domain on SRrpI 29 was identified as follows: 20 μ9 of the vector 'bluescript' with the SRrpI 29 insert (pKSSRrp129) was diluted to a volume of 500 μΐ with 50 mM TrisCl pH 7.5,10 ΓΠΜ MnCI 2 ,50 μρΛηΙ BSA and digested with 1 unit of DNAse I (Pharmacia, 27-0514) at 37 °C for 3 minutes. Doublestranded fragments of approximately 50-2000 bp generated in that way were repaired to blunt ends by treatment with T4 and Klenow polymerase (5 units each) for one hour and then phosphorylated with T4 kinase (5 units) for an additional hour. The resulting fragments were fractionated on an 1% agarose gel. Fragments between 50 and 800 bp were excised from the gel and the DNA was eluted from the agarose (QIAquick gel extraction). A random fragment library was made by ligating the DNA fragments into the Smal site of linearised pGAD 424 plasmid (Clontech). The library plasmids were then transformed into E. coll by electroporation and amplified on large plates (25 x 25 cm) to ensure representativity (100000 colonies). The plasmids were extracted and transformed by the modified lithium acetate method (Gietz and Schiestl, 1991) into the yeast strain Y153 (Durfee ef a/., 1993) which carried the pRS GALCTD plasmid as a bait. 80000 yeast transformants were selected on minimal medium lacking leucine, tryptophan and histidine but containing 30 mM 3-aminotriazole (3-AT), and incubated at 30 °C for 5 days. 11 colonies turned blue in the presence of the chromogenic substrate X-gal. The cloned inserts from these 11 blue colonies were amplified by whole-cell PCR (Satheef a/., 1991) using primers corresponding to regions of the vector flanking the cloning site. All 9 amplifiable inserts were in a size between 300 and 500 bp. After purification on a pre-parative agarose gel, the amplified fragments were directly sequenced and compared to the SRrpI 29 DMA sequence. The grey box in pKSSRrp129 represents the interaction domain, the white box represents human flanking cDNA sequence, the thin line represents plasmid vector DMA. a The experimental procedure is described in Figure 2 ; b The sequence analysis revealed 7 distinct cDNAs, two clones were obtained in duplicate.
be slightly staggered, while in the presence of magnesium (II) single strand breaks are produced (Campbell and Jackson, 1980 ; Table 1 ). The size-selected, blunted fragments were inserted into the GAL4 activation domain-tagged yeast expression vector pGAD424 (Clontech). The library of random fragments was amplified and tested in the two-hybrid assay as described in Table 1 . The shortest positive clone that we isolated, SRrpI 29Δ7, is 100 amino acids long (the boxed region in Figure 1 B ) and includes the entire region of homology between SRrpI 29 and C10. The interaction of Δ7 with the CTD was comparable in strength to that of the original SRrpI 29 clone of 1436 bp, as estimated from the levels of the -galactosidase reporter gene activity (not shown). A sequence comparison with the CTD-binding proteins isolated by Yuryev et a/. (1996) revealed that two of these, rA1 and rA9, share a similar CTD interaction domain at their very C-terminus ( Figure 1A and B) . The percentage of identity in pairwise comparisons between the four proteins within the CTD interaction domain ranges from 63% to 67%, with the exception of C10 and rA9, which are 94% identical. Outside of the CTD interaction domain, C10 shows 46% identity with rA9 (over 52 amino acids), whereas SRrpI 29 diverges considerably from both rA1 and rA9.
We decided to focus on the cloning of full length SRrpI 29. By Northern blot analysis (Multiple Tissue Northern, Clontech), we detected in all tissues a single band migrating slightly slower than the 6 kb marker. We screened a \GT10 cDNA library prepared from the BJA-B cell line (a kind gift of M. Busslinger, IMP Vienna) with a random primer-labelled probe from a cDNA fragment of SRrpI 29 outside of the CTD interaction domain. The longest cDNA isolated contained 2051 bp, extending the known sequence by 648 bp.
A search of the EMBL Nucleotide Sequence Database with the SRrpI 29 sequence using the tFASTA program showed a large stretch of identity to a genomic clone of about 100 kb (Stanford Human Genome Center: B271E1; Accession No.: AC000015) that originates from the chromosomal region 21 q22.3, and is associated with the chromosomal marker D21S25 ( Figure 1C ). This region contains genes responsible for progressive myoclonus epilepsy (EPM1) and autoimmune polyglandular disease type I (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, APECED). However, no relation between these diseases and any sequence corresponding to our clone has been reported so far.
Upon a closer look at the genomic sequence surrounding the region of identity to SRrpI 29, it became apparent that it was part of a large open reading frame. This suggested that the ORF might be part of a very large exon consisting of more than 2600 nucleotides. In addition to this large exon, we found a second region on the genomic clone with 100% identity to the SRrpI 29 cDNA sequence (position 3825-4171 on the SRrp129 full length cDNA sequence); corresponding to an exon of 347 nucleotides (exon 2, Figure 1C ). These two exons are separated by an intron of 1068 nucleotides, which conforms to the 'GT-AG' rule and has a 5' splice site compatible with the consensus sequence (intron 1, Figure 1 C) . Additional 3' genomic sequence information is currently not available from the Stanford database.
In the database search, we also found EST clones from several different tissues and developmental stages (human fetal tissues and adult tissues) covering almost the entire open reading frame of exon 1 (Figure 1C ), suggesting that the SRrpI 29 gene is widely expressed in human cells (not shown). Indeed, we were able to amplify a fragment by PCR from both human genomic DNA (a kind gift of J. Silke) and human lymphocyte cDNA (Clontech). The identity of the amplified fragments was confirmed by reamplification with specific nested primers, sequencing from both ends, and restriction digest analysis. These results further corroborate that this long exon is part of an expressed gene.
Because we did not know if we had the entire cDNA sequence of SRrpI 29, we performed a 5'-RACE (Rapid Amplification of cDNA Ends, Marathon ready cDNA, Clontech). We could amplify a single fragment of about 1350 base pairs when we used a gene specific primer about 100 bp downstream of the first AUG (Figure 1 C) . Sequencing from both ends and reamplification with specific nested primers revealed that this additional cDNA sequence corresponded to the genomic sequence immediately upstream of the large open reading frame (exon 1, Figure 1C ). Sequencing of the region immediately upstream of the first AUG in the first large exon confirmed the presence of stops in all three reading frames ( Figure 1C) . Taken together, these data demonstrate the existence of a transcript of at least 5 220 nucleotides starting with an unusually long first exon (3823 nucleotides), which includes an untranslated leader sequence of 1210 nucleotides and codes for an open reading frame of 871 amino acids (Figure 1 C) . While the average length of vertebrate exons range around 60 to 210 nucleotides (Dorit et a/., 1990 ), a few exceptionally large exons have also been reported: for example, an exon of human clotting factor VIII gene is 3106 nucleotides long, and an exon of human apolipoprotein-B gene even has a length of 7572 nucleotides (Hawkins, 1988) . The translation of the reconstructed SRrp129 reading frame would yield a protein of 1148 amino acids with a predicted molecular weight of 129 kDa. Strikingly, we found a serine/arginine-rich (SR) region, that is a typical feature of proteins involved in splicing and which has also been found in other proteins interacting with the CTD (Yuryev et a/., 1996 ; see also Table 2 ). Therefore, this SRcontaining 129 kDa protein was named SR-related protein 129 (SRrpI 29). The nucleotide and amino acid sequences of SRrp129 are accessible at the EMBL Nucleotide Sequence Database under the accession number Y11251.
SR proteins are a family of splicing factors that are involved in early steps of the splicing reaction, such as splice site selection and early spliceosome assembly (Fu, 1995; Manley and Tacke, 1996) . A database search with the FASTA algorithm detected many different SR proteins with significant homologies to SRrp129 within their SR domains. Table 2 describes the serine/arginine-rich domains of eight selected proteins identified in this search: SRp75, SRp55-3, and SC35 are three human splicing factors of the SR protein family, U2AF is classified as an SR-related protein with a N-terminal SR domain (Fu, 1995) . SRcyp, rA1 and rA9 are large serine/arginine-rich proteins that have recently been found to interact with the pol II CTD (Yuryev et a/., 1996; Bourquinefa/., 1997) . The serine/arginine-rich domains of the four CTD-binding proteins listed here have a similar sehne, arginine and SR/RS dipeptide content. These sequence features indicate that these proteins are probably related to the SR splicing factors.
Taken together, our results suggest the existence of a larger family of related serine/arginine-rich proteins that interact with the CTD of RNA polymerase II. Hence, SRrp129, C10, rA1 and rA9 may be grouped together (Figure 1 A) . All four proteins are large and contain a related SR domain and a related CTD interaction domain at the Cterminus, which does not overlap with the SR domain. Two other clones identified by J. Corden and colleagues, rA4 and rA8, share a SR domain, a different type of CTD-binding region and an RNA recognition motif (Yuryev ef a/., (A) Before initiation, the CTD is hypophosphorylated and interacts with components of the basal transcription apparatus. (B) Upon initiation/promoter clearance, the CTD becomes highly phosphorylated. Now it can associate with spliceosome assembly factors including SR domain proteins (Yuryev ef a/., 1996; and this paper) and polyadenylation site recognition factors (McCracken ef a/., 1997). (C) Auxiliary splicing factors dissociate from the CTD and bind to freshly synthesized RNA. (D) Polyadenylation factors bind to the poly A site, which allows for cleavage/polyadenylation of the primary transcript. (E) Downstream of the polyadenylation site, the polymerase synthesizes a stretch of uncapped, unstable RNA, the CTD may become dephosphorylated, and RNA polymerase is released from the template. 1996). In SRcyp, the SR domain itself is responsible for CTD interaction (Bourquin ef a/., 1997) . Therefore, remarkably, three different types of protein domains can mediate the interaction with the CTD among the seven serine/arginine-rich proteins isolated to date (Yuryev ef a/., 1996; and our results). SR domains were found to be involved in protein-protein interactions (Manley and Tacke, 1996) . A network of interactions with the CTD and with other SR proteins is therefore possible. The interactions of SRcyp and of rA9 with the CTD have been confirmed by cell-free binding studies, and both proteins bind the phosphorylated form of the CTD (Yuryev ef a/., 1996; and our results). Thus, it seems possible that these proteins could undergo multiple interactions with the CTD in a larger protein complex that would link transcriptional elongation to the splicing apparatus (see model in Figure 3 ). Several observations support, or are consistent with, a role of the CTD in splicing. A phosphorylated form of pol II can be immunoprecipitated together with splicing factors, using SR-reactive monoclonal antibodies (Mortillaro et a/., 1996) . Furthermore, intron containing pol II genes that are ectopically transcribed by pol III cannot be spliced, indicating that splicing depends on the presence of pol II in vivo (Sisodiaef a/., 1987) . Moreover, anti-CTD antibodies, as well as CTD peptides, inhibit cell-free splicing reactions (Yuryev ef a/., 1996) . Splicing on the nascent transcripts might be initiated by components of the early spliceosomal complex that are transferred from the CTD to the RNA (Figure 3) . Such CTD-bound factors could be directly active in splicing or recruit early splicing factors in a regulated manner. Cotranscriptional splicing is likely to contribute to efficient synthesis and processing of the often very long pol II transcripts in higher eukaryotes. Tethering of splicing components, notably SR proteins, to the CTD could also provide a mechanism to control alternative splicing on the nascent transcript.
